A new recurring chromosome abnormality was identified in 8 of 621 consecutive successfully karyotyped adults with de novo acute leukemia. These eight patients had trisomy 13 as the sole cytogenetic abnormality. On central morphologic review, five cases were classified as subtypes of acute myeloid leukemia, one as acute mixed lymphoid and myeloid leukemia, one as acute lymphoid leukemia, and one as acute undifferentiated leukemia. Blasts of all eight cases expressed one or more myeloid differentiation antigens. Three also expressed T-lineage-associated antigens; however, none of these had rearrangement of the T-cell receptor B, 7, or 6 genes. Four of six cases tested were TdT positive. All eight patients with trisomy 13 were treated HE CLINICAL and potential biologic significance of T clonal chromosome abnormalities in acute leukemia has gained considerable attention in recent year^."^ With current cytogenetic techniques, clonal abnormalities are detected in the majority of cases. A large number of specific structural and numerical abnormalities have been identified, some of which have been associated with characteristic morphologic, immunologic, and clinical features, eg, t( 15; 17)(q22;qll-q12) with acute promyelocytic leukemia or t(8; 14)(q24;q32) with surface immunoglobulin (Ig) positive B-cell acute lymphocytic leukemia. Furthermore, retrospective and prospective studies have shown that specific chromosome abnormalities are of significant prognostic ~a l u e .~,~ Abnormalities such as inv( 16), t(15;17), and t(8;21) in myeloid leukemias have been associated with longer survivals, whereas monosomy 7, llq23 rearrangements and the Philadelphia chromosome are predictors of a poor outcome. Large prospective clinical trials are necessary to assess the prognostic significance of other, less common recurring chromosome abnormalities in acute leukemia. The identification of risk groups based on specific chromosomal findings will have major clinical implications, especially with regard to the design of more risk-specific treatment protocols. In addition, the finding of new recurring
with intensive induction chemotherapy; only three entered a short-lived complete remission. Survival of patients with trisomy 13 ranged from 0.5 to 14.7 months, and was significantly shorter than that of the remaining patients (median 9.5 w 16.2 months, P = .007). We conclude that trisomy 13 is a rare, recurring clonal chromosome abnormality in acute leukemia associated with a poor prognosis. Malignant transformation of an immature hematopoietic precursor cell is suggested by the expression of antigens characteristic of both the myeloid and lymphoid lineage, the high incidence of TdT positivity, and the morphologic heterogeneity in these leukemias. 0 1990 by The American Society of Hematology. chromosome abnormalities will provide insight into the gene region(s) that may be important in malignant transformation.
A new recurring chromosomal abnormality in leukemia is described in this report. We report the morphologic, immunologic, genotypic, and clinical data from eight adult patients with de novo acute leukemia who presented with trisomy 13 as the sole karyotypic abnormality.
PATIENTS AND METHODS

Patients.
Of 621 adult patients with newly diagnosed de novo acute leukemia referred for cytogenetic analysis as part of a prospective Cancer and Leukemia Group B study (CALGB 8461), eight patients (1.3%) were found to have trisomy 13 as the sole cytogenetic abnormality. All patients were treated according to CALGB protocols. Patients 1 through 5 were entered on Protocol 8525' (daunorubicin 45 mg/m2/d x 3 days [30 mg/m2 > 60 years], cytarabine 200 mg/m2/d x 7 d); patient 6 on Protocol 83216 (daunorubicin 45 mg/mz/d x 3 days, cytarabine 100 mg/m2/d x 7 days); and patients 7 and 8 on Protocol 8513 (daunorubicin 45 mg/m2/d x 3 days and mitoxantrone 10 mg/m2/d x 3 days, respectively, vincristine 2 mg, prednisone 40 mg/m2/d x 21 Immunophenotyping. Immunophenotypic analysis was performed in central reference laboratories. Heparinized bone marrow or blood samples from acute myelogenous leukemia (AML) and acute lymphocytic leukemia (ALL) patients were sent to Dartmouth-Hitchcock Medical Center, Hanover, NH, or to the University of California, San Diego Cancer Center, respectively. Antigenic expression by leukemic cells was determined by indirect immunofluorescence and flow cytometry using previously described methods."*'* Antigens that were tested for (and monoclonal antibodies [MoAbs] used) included: C D l l b ( M o l ) , CD13 (My7 or MCS-2), CD14 (My4), CD15 (PM-81), and CD33 (My9) (myeloid-lineage associated); CD34 (MylO) (hematopoietic progenitor cells); CD19 (B4) (B-cell associated); CDl (OKT6), CD2 (T11 or Lyt3), and CD5 (T101) (T-cell associated); CDlO (J5) (early lymphoid); and HLA-DR (I2 or 9-49). Cases were scored as positive when 220% of cells expressed an antigen. TdT expression was determined by immunofluorescence.' ' TCR gene rearrangement analyses were performed on leukemic cells from patients 2,3,7, and 8. Ig gene rearrangement studies were also done in cases 7 and 8. High-molecular-weight DNA was extracted from blood (patient 7) or bone marrow (patients 2,3, and 8) leukemic cells and digested with BamHI, EcoRI, HindIII, or Xba I restriction endonucleases as described." The DNA fragments were sizefractionated by agarose-gel electrophoresis, transferred by the Southern method, and hybridized to nick-translated "P-labeled DNA probes. Germ-line or rearranged Ig and TCR gene configurations were visualized by autoradiography.
The following probes were used: TCR-8, a 770-bp PstIIPstI fragmentI3; TCR-y, a 1.6-kb EcoRIIEcoRI fragmenti4; and TCR-6, a 1.6-kb XbaI/XbaI fragment.I5 In patients 7 and 8 the following additional probes were used: JH, a 3.2-kb EcoRIIHindIII fragment detecting all heavy-chain joining regionsi6; CK, a 2.5-kb EcoRI/ EcoRI fragment detecting the constant region of I~K " ;
and CX, a 0.8-kb BamHI/HindIII fragment."
Because 24 cases were either unevaluable or pending FAB classification, 597 of the 621 successfully karyotyped patients were included in subsequent analyses. Clinical and hematologic parameters were compared between the patients with or without trisomy 13. Hypotheses of no difference in the distribution of discrete variables between the two groups were tested using the Fisher exact test, and in the distribution of continuous variables using the Mann-Whitney rank test. The significance level was a = .05. Survival and complete remission (CR) duration were plotted Ig and T-cell receptor (TCR) gene rearrangement studies.
Statistical analysis.
from life tables using the method of Kaplan and Meier. Differences between these curves were analyzed by the log-rank test. Survival was calculated from the date of diagnosis to the date of death or censored at last follow-up. Remission duration was calculated from the date of first CR to the date of relapse or censored at the last known date free of disease.
RESULTS
Cytogenetics.
All patients had one clone with trisomy 13 as the sole abnormality (Table 1) . Patient 1 had a second hyperdiploid clone with two extra copies of chromosome 13, and patient 8 had a second hypertetraploid-abnormal clone. In five of the eight patients, 50% or more of the metaphases showed the extra chromosome 13. In three patients (those with M4 or M5 AML) only 17% to 29% of the metaphases demonstrated trisomy 13. Among the patients also studied at first relapse, two had the same abnormality found at diagnosis, whereas one had only normal metaphase cells detected.
Patients 1 through 5
were diagnosed as AML: FAB M1 (n = l), M2 (n = l), M4 (n = 2), M5A (n = 1). Patient 6 was classified as acute leukemia, mixed lymphoid (FAB L2), and myeloid (FAB M5). While most of the blasts from this case were morphologically lymphoid, definite promonocytes were present in the blood and bone marrow (Figs 1 A and B ). Patient 7 was diagnosed as ALL (FAB L2); the majority of the neoplastic cells were typical lymphoblasts, yet a significant minority possessed cytoplasmic tails or projections similar to those seen in "hand mirror" lymphoblasts ( Fig IC) . Patient 8 was classified as acute undifferentiated leukemia (AUL). Although most of the blasts simulated L2 lymphoblasts, there were many large pleomorphic blasts with cytoplasmic buds ( Fig 1D) . Cytochemical staining in six cases ( Table 2) showed evidence of myeloid differentiation (23% PX or SBB positive cells). However, a high percentage of blasts were positive for PX or SBB in only patients 3 and 4. Compared with patients without trisomy 13, patients with trisomy 13 had a significantly lower median percentage of blasts positive for PX (36% v 3%; P = .038) and SBB (60% v 6%; P = .013).
Although neoplastic cells in four of eight cases exhibited a positive reaction (220% of blasts) with ANAE, none showed Morphology and cytochemistry. For personal use only. on November 10, 2017. by guest www.bloodjournal.org From the diffuse. intense stain characteristic of monocytic differentiation. Blasts of only one patient had rare Auer rods.
Blasts of all cases showed reactivity with one or more MoAbs directed against myeloid antigens (CDllb, CD13. CD14. CDIS, CD33. or CD34) ( Table 3 ). Leukemic cells from three patients expressed both myeloid and T-lineage antigens. Blasts of patients 2 and 3 were both CDS' while expressing CDllb. CD13. CD15. CD33. and CD34: or CD14. C D I . and CD33. respectively. Blasts from patient 7 had a T-lineage immunophenotype (TdT' . CDlO ' . CDI ' . CD2 ' . CDS ' ) but also expressed the CDI 3. CD14. and CD34 antigens. Double-immunofluores-Immunophenotypinr. cence could not be performed in these cases to determine whether there was cocxpression of antigens on the same cell or concurrent proliferation of two distinct blast populations.
All cases tested had expression of HLA class I1 antigens. and four of six cases tcstcd were TdT positive. None cxprcsed the B antigen CD19.
TCR gene rearrangement studies were performed in cases 2. 3. and 7 with leukemic blasts that expressed T-cell-associated antigens. and also in case 8 which was diagnosed as ALL. All four patients had germ-line TCR 6. y. and d gene configurations. A monoallelic Ig heavy-chain gene rearrangement was
Ir and TCR gene rearranKement studies.
For personal use only. on November 10, 2017. by guest www.bloodjournal.org From -J ---I Fig 1 . (Cant'd) .
observed in patient 8. No rearrangement of either light chain was found in the twocases examined.
Clinical characrerisrics. The clinical features of the patients with trisomy 13 are summarized in Table 2 . There wcrc six men and two women ranging in age from 34 to 68 years. One patient had leukemic infiltration of the skin and gums. two had lymphadenopathy. and one had splcnomep l y . None of the patients prcsented with hepatomegaly or a mediastinal mass.
All of the prtients had anemia at diagnosis. The most striking hematologic finding was a high leukocyte count grcatcr than SO.OoO/pL in five of the patients. All threc patients with monocytic leukemia (3 through 5 ) had leukocyte counts greater than 1OO.OOO/pL. The median platelet count was 91.000/pL. Data on serum lysozyme were available for only patients 3 and 4. who both had elevated levels. There were no statistically significant dilTerences with regard to the presenting hematologic parameters between the patients with or without trisomy 13.
Only three patients (3. 6 . and 8) achieved CR. which lasted 6.4. IO. I . and I .9 months. respectively. Two patients (4 and 5 ) did not respond to, and three ( I . 2. and 7) died during. induction chemotherapy. All patients with trisomy 13 arc now dead: survival ranged from 0.5 to 14.7 months For personal use only. on November 10, 2017. by guest www.bloodjournal.org From (median 9.5 months). The median survival of the patients with trisomy 13 was significantly shorter than that of the other 570 patients with acute leukemia (median 16.2 months; P = .007; see Fig 2) . When ALL cases were excluded, survival of the patients with trisomy 13 was still significantly shorter (P = .026).
DISCUSSION
In this prospective study of 621 adults with cytogenetically characterized de novo acute leukemia, eight patients presented with trisomy 13 as the only clonal chromosome abnormality. By immunophenotyping all eight cases expressed myeloid antigens giving evidence for myeloid differentiation. However, blasts of three patients displayed both myeloid and lymphoid differentiation antigens; blasts of two had additional expression of the T-cell-associated antigen CD5 and the third showed a phenotype consistent with a common thymocyte (TdT+, CD1+, CD2+, CD5+) .I8 The expression of both myeloid and lymphoid associated antigens in acute leukemia has been widely re~ognized.'~-~' It is postulated that these leukemias, commonly referred to as mixed-lineage leukemias, represent clonal expansions of multipotent progenitor cells. Whether these leukemias arise from transformation of uncommitted progenitor cells that express antigens associated with different cell lineages,*' or if transformational events in these leukemias generate expression of aberrant gene products" is unresolved. The significance of the expression of the T-lineage-associated antigen CD5 on otherwise myeloid-lineage leukemias is unknown; it is unclear whether a normal counterpart exhibiting such a phenotype exists. The findings in patient 7 are intriguing. To our knowledge, all leukemias exhibiting the more mature phenotype of a common thymocyte have been shown to undergo rearrangement of their TCR whereas our For personal use only. on November 10, 2017. by guest www.bloodjournal.org From patient retained the TCR 0, y, and 6 genes in germ-line configuration. Moreover, a high percentage of blasts displayed myeloid differentiation antigens and the CD34 antigen, a marker of immature hematopoietic progenitor cells that is rarely expressed on T-lineage leukemias.24 The asynchrony in immunophenotypic and genotypic differentiation in this case may suggest a mechanism of aberrant gene expression induced by malignant transformation of the clonogenic cell.
Morphologically, these eight cases were heterogeneous. Five had subtypes of AML. The others were classified as ALL, acute mixed lymphoid and myeloid leukemia, and AUL. Although over 80% of the leukemic cells from the two latter patients were positive for TdT, reactivity with lymphoidassociated antigens was not seen. In contrast to the consistent expression of myeloid antigens, there was little cytologic evidence for myeloid differentiation. When compared with the other protocol patients, the percentage of blasts positive for PX and SBB was significantly lower, indicating a rather restricted myeloid differentiation potential. The immature nature of these leukemias is further suggested by the high incidence of TdT expression. TdT expression in myeloid leukemias is said to be more prevalent in biphenotypic and morphologically immature leukemias (eg, MO or Ml).25 Our findings support this conclusion. Of the four TdT positive cases studied, one was morphologically undifferentiated, one
Survival (Months)
had a mixed T-lymphoid/myeloid immunophenotype, and another had two morphologically distinct blast populations.
Clinically, trisomy 13 indicated an unfavorable prognosis. Only three patients achieved short-lived remissions, and survival was significantly shorter than that of patients without trisomy 13. However, this result has to be viewed with some caution, because the number of patients with trisomy 13 is still small. Nevertheless, support for our data comes from 12 previously reported cases of le~kemia'~'~' with trisomy 13 as the sole cytogenetic abnormality ( Table 4 ). The few clinical data available on these patients are consistent with our findings. Most importantly, the patients had very short survival times. Ten patients were diagnosed as myeloid leukemias, one as mixed lineage leukemia, and one as undifferentiated leukemia. Immunophenotypic data are given only in one case.26 Similar to one of our patients, this patient had both a lymphoid and a myeloid population of blasts; these were undifferentiated by cytochemical stains, but when studied by double-immunofluorescence, one was TdT+, Leu-M1-, and the other was TdT-, Leu-Ml', respectively.
A similar propensity for morphologic and immunologic lineage heterogeneity as observed in trisomy 13 has been demonstrated for other recurring chromosome abnormalities; the Philadelphia chromosome and 1 lq23 abnormalities are classic example^.^^.^^ Within the myeloid series, lineage For personal use only. on November 10, 2017. by guest www.bloodjournal.org From heterogeneity has been shown for leukemias exhibiting trisomy 8 or monosomy 7. Such cases can involve the granulocytic, erythrocytic, and megakaryocytic cell lineages.40
In conclusion, trisomy 13 is another rare, recurring, chromosome abnormality in acute leukemia. Immunologic, genotypic, and morphologic results are consistent with malignant transformation of an immature hematopoietic precursor cell giving rise to morphologic and immunophenotypic lineage heterogeneity. Most importantly, trisomy 13 seems to constitute a subgroup of leukemias with a significantly inferior prognosis.
